PRN: Research and Markets - Renal Cluster Drug Development Pipeline Review 2017 - Key Companies are Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals & Vidasym

29/mag/2017 18:20:13 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Research and Markets - Renal Cluster Drug Development Pipeline Review 2017 - Key Companies are Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals & Vidasym

 
[29-May-2017]
 

DUBLIN, May 29, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Renal Cluster Drug Development Pipeline Review, 2017" report to their offering.

Research and Markets Logo

This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. There are a total of 39 products in development for this indication, by 28 companies and five academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Pharmaxis, Cellmid and Vascular Biogenics.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. There are a total of 59 products in development for this indication, by 48 companies and two academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals and Vidasym.

While kidney transplant rejection treatments are largely focused on immune system molecular targets such as tumor necrosis factor alpha and complement factors, a range of cellular signaling components are being pursued in the other three key indications, including the activin receptors, cyclin dependent kinases, and growth factor receptors.

Companies Mentioned

  • A1M Pharma AB
  • AbbVie Inc
  • Allergan Plc
  • Alloksys Life Sciences BV
  • Am-Pharma BV
  • Amgen Inc
  • Angion Biomedica Corp
  • Apceth Biopharma GmbH
  • Apellis Pharmaceuticals Inc
  • Apollo Endosurgery Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atox Bio Ltd
  • BLR Bio LLC
  • Bayer AG
  • BiOrion Technologies BV
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • CSL Ltd
  • (70+ Others)

Key Topics Covered:

  1. Report Guidance
  2. Executive Summary
  3. Introduction
  4. Report Coverage
  5. Therapeutics Development
  6. Therapeutics Assessment
  7. Companies Involved in Therapeutics Development
  8. Dormant Projects
  9. Discontinued Products
  10. Product Development Milestones

For more information about this report visit http://www.researchandmarkets.com/research/8gl35j/renal_cluster 

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl